Poolbeg Pharma's Jeremy Skillington joins Proactive London's Katie Pilbeam to discuss their plans to list on the London market. The firm is a spin-out of Open Orphan who announced they're seeking admission to trade on the AIM in London and raise cash to fund clinical trials for its flu treatment.
Open Orphan spin-out Poolbeg Pharma 'ready to go' with plans to list on London market
